{"denoms":[{"counts":[{"groupId":"BG000","value":"254"},{"groupId":"BG001","value":"253"},{"groupId":"BG002","value":"507"}],"units":"Participants"}],"groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.","id":"BG000","title":"CAPOX+ Zolbetuximab"},{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.","id":"BG001","title":"CAPOX+ Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.1","value":"58.6"},{"groupId":"BG001","spread":"13","value":"56.7"},{"groupId":"BG002","spread":"12.6","value":"57.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"192"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"315"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"17"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"242"},{"groupId":"BG001","value":"241"},{"groupId":"BG002","value":"483"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"316"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"184"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"315"}]}],"title":"Asia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"192"}]}],"title":"Non-Asia"}],"paramType":"NUMBER","title":"Region (Asia vs Non-Asia)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"377"}]}],"title":"0-2 metastatic sites"},{"categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"130"}]}],"title":">=3 metastatic sites"}],"paramType":"NUMBER","title":"Number of organs with metastatic sites","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"150"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"357"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Gastrectomy","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis set (FAS) included all participants who were randomized to 1 of the treatment arms."}